 | • レポートコード：D0-MOR-AP0009 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、先端巨大症治療の世界市場について調査・分析した資料で、先端巨大症治療の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The Acromegaly Treatment Market is expected to register a CAGR of 7.4% during the forecast period. Acromegaly is a hormonal disorder that develops in the pituitary gland which produces too much growth hormone during adulthood which results in an increase in bone size, including those of hands, feet, and face. Acromegaly usually affects middle-aged adults. In children, too much growth hormone can cause a condition called gigantism and may have exaggerated bone growth and an abnormal increase in height. A common sign of acromegaly is enlarged hands and feet. In adults, the tumor is the most common cause of too much growth hormone production. Some of the complications associated with the progression of acromegaly are hypertension, osteoarthritis, diabetes mellitus, goiter, and vision loss.
According to the National Institutes of Health (NIH) and Endocrine Society, estimates there are about 69,000 individuals living with acromegaly worldwide. However, symptoms of acromegaly may develop slowly, the disorder may often remain unrecognized and may, therefore, be underdiagnosed, making it difficult to determine the true frequency of acromegaly in the general population.
Furthermore, increasing incidence of pituitary tumors and acromegaly, prevalence of genetic diseases, changing lifestyle and increasing investments in R&D for developing new molecules are driving the growth of acromegaly treatment market.
Key Market Trends
Somatostatin Analogs Segment is Expected to Hold a Major Market Share in the Acromegaly Treatment Market
Somatostatin analogs segment holds a significant market share in the acromegaly treatment market and is anticipated to show a similar trend over the forecast period owing to the wide availability of drugs and cost-efficiency. Somatostatin analogs have been prescribed as the first-line treatment options as these are highly effective. Some of the available marketed drugs are somavert, Signifor LAR, Sandostatin LAR, Somatuline Depot, and Parlodel. According to the National Organization for Rare Disorders, acromegaly affects males and females in equal numbers. This disorder occurs in approximately 50 to 70 people per million population worldwide. Amryt, a clinical-stage specialty pharmaceutical company focused on best-in-class treatments for orphan diseases. United States Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s drug compound, AP102, which has the potential to treat patients with acromegaly. Furthermore, technological advancements coupled with government support, and promising pipeline drugs are the key driving factors in the somatostatin analogs segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global acromegaly treatment market due to the high demand for innovative products in this region. According to the National Institutes of Health (NIH) and Endocrine Society, in 13 studies of acromegaly prevalence since 1980 researchers estimate that roughly 24,000 individuals are living with acromegaly in the United States, of which an estimated 8,000 people are treated chronically with somatostatin analog injections. Furthermore, the presence of top pharma and biotech companies that are involved in the development of products for acromegaly treatment and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
Competitive Landscape
The Acromegaly Treatment Market is Consolidated competitive and consists of a few major players. Some of the prominent players operating in the acromegaly market are Pfizer Inc, Novartis AG, Validus Pharmaceuticals LLC, and Ipsen. Some of the companies involved in developing products for acromegaly are Chiasma, Inc, Crinetics Pharmaceuticals, Ionis Pharmaceuticals Inc and Midatech Pharma Plc.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence and Incidence of Acromegaly and Pituitary Tumors
4.2.2 Growing Awareness Regarding Acromegaly Disease Worldwide
4.2.3 Technological Advancements in Development of New Drugs for Acromegaly
4.3 Market Restraints
4.3.1 Complications Associated with the Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Somatostatin Analogs
5.1.2 Growth Hormone Receptor Antagonist (GHRA)
5.1.3 Dopamine Agonists
5.1.4 Other Product Types
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc
6.1.2 Novartis AG
6.1.3 Validus Pharmaceuticals LLC
6.1.4 Ipsen
6.1.5 Chiasma, Inc
6.1.6 Crinetics Pharmaceuticals
6.1.7 Ionis Pharmaceuticals Inc
6.1.8 Midatech Pharma Plc
7 MARKET OPPORTUNITIES AND FUTURE TRENDS